<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>CIPLA</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">CIPLA</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="cipla-limited" class="section level1">
<h1>Cipla Limited</h1>
<p><a href="/reports01/index/industry/rp-Pharmaceuticals.html">Pharmaceuticals</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.CIPLA.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.CIPLA.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.CIPLA.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.CIPLA.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.CIPLA.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.CIPLA.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.CIPLA.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.CIPLA.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.CIPLA.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-03 </em></p>
<div id="cipla-limited-cipla-analysis-headwinds-tailwinds-growth-prospects-and-key-risks" class="section level3">
<h3>Cipla Limited (CIPLA) Analysis: Headwinds, Tailwinds, Growth Prospects, and Key Risks</h3>
<p><strong>Date of Analysis:</strong> Based on Q2 FY26 Earnings (ended Sep 30, 2025), Earnings Call Transcript, Investor Presentation, and Related Disclosures (Oct/Nov 2025).</p>
<p>Cipla reported record Q2 FY26 revenue of <strong>INR 7,589 Cr (+8% YoY)</strong>, EBITDA of <strong>INR 1,895 Cr (25% margin)</strong>, and PAT of <strong>INR 1,351 Cr (+4% YoY)</strong>. Growth was balanced across geographies: One India (+7%), North America ($233 Mn), One Africa (+5% USD YoY), EMEU (+15% USD YoY). Strong balance sheet with <strong>net cash of INR 9,901 Cr</strong>. Leadership transition announced: Umang Vohra steps down Mar 31, 2026; Achin Gupta appointed MD &amp; GCEO designate (Jan 1, 2026) and full role from Apr 1, 2026.</p>
<div id="tailwinds-positive-momentum" class="section level6">
<h6>Tailwinds (Positive Momentum)</h6>
<ul>
<li><strong>Diversified Revenue Growth</strong>: Balanced contributions from all key markets (India 41%, US 27%, Africa 16%, EMEU 13%). No over-reliance on single geography/product.</li>
<li><strong>India Strength</strong>: Branded Rx chronic mix at 61.8% (up YoY); key therapies (urology +17%, cardiac +13%, anti-diabetes +10%, dermatology +18%) outperforming IPM market (8%). Foracort #1 IPM brand; 29 brands &gt;INR 100 Cr; #1 volume player (2B+ units). Trade generics double-digit growth; Consumer Health anchors (Nicotex, Omnigel, Cipladine) #1 in segments.</li>
<li><strong>US Traction</strong>: Albuterol MDI #1 (22% share, 50M+ units supplied); Lanreotide 22% share. First US biosimilar (Filgrastim) launched.</li>
<li><strong>Strategic Partnerships</strong>: Eli Lilly tie-up for <strong>Yurpeak (tirzepatide)</strong> in India (obesity/diabetes; ~200 Mn eligible patients). Exclusive nationwide rights; dedicated sales force added. Potential for semaglutide post-approval.</li>
<li><strong>Pipeline &amp; Innovation</strong>: US: 4 respiratory (incl. gAdvair Q4 CY26) + 3 peptides (incl. liraglutide) by CY26; 285 ANDAs/NDAs under review (180 approved). India: New launches (e.g., Huena, ZEMDRI, Cipenmet for AMR; Empacip, Afrezza). R&amp;D at 7.1% of sales (INR 539 Cr).</li>
<li><strong>Financial Health</strong>: Debt low (INR 467 Cr); high cash enables investments. ESG progress (76% Scope 1/2 emission cut; water positive; ZWTL certified); MSCI ESG upgraded to A.</li>
<li><strong>Regulatory Wins</strong>: Bommasandra site VAI by USFDA.</li>
</ul>
</div>
<div id="headwinds-challenges" class="section level6">
<h6>Headwinds (Challenges)</h6>
<ul>
<li><strong>India Slowdown</strong>: Branded Rx at 7% YoY (vs. IPM 8%); respiratory impacted by weak acute season (Q1 carryover). GST transition caused brief disruption.</li>
<li><strong>US Revlimid Decline</strong>: gRevlimid contribution “very small” in Q3 FY26 (near-patent expiry Jan 2026); base business growth expected but timing gaps in pipeline offsets.</li>
<li><strong>Margin Pressures</strong>: Revised FY26 EBITDA guidance <strong>22.75-24%</strong> (down from 23.5-24.5%) due to higher R&amp;D (+50 bps of revenue), Revlimid drop, Q4 seasonality/low margins. Q2 gross margin 67% (seq. dip 160-170 bps from mix, R&amp;D materials, pricing).</li>
<li><strong>ESG Dip</strong>: NSE rating revised 65→64 due to Cipla USA voluntary recall (Jul 2025).</li>
<li><strong>Macro/Execution</strong>: Africa tender variability; API revenue -7% YoY.</li>
</ul>
</div>
<div id="growth-prospects" class="section level6">
<h6>Growth Prospects</h6>
<table>
<colgroup>
<col width="29%" />
<col width="41%" />
<col width="29%" />
</colgroup>
<thead>
<tr class="header">
<th>Segment</th>
<th>Key Drivers</th>
<th>Outlook</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>One India (41% rev)</strong></td>
<td>Yurpeak/semaglutide entry (Tier 2/3 focus); chronic CAGR 16.4% (FY21-25); 6+ new launches/Q (AMR, CNS, GI, derm); trade/consumer double-digit.</td>
<td>Mid-teens potential; market-outperformance via execution.</td>
</tr>
<tr class="even">
<td><strong>US (27% rev)</strong></td>
<td>Pipeline (gAdvair, QVAR?, peptides); biosimilars ramp; $1B run-rate FY27 (directional). Albuterol/Lanreotide scale.</td>
<td>Strong; launches derisked (3/4 respiratory from US sites).</td>
</tr>
<tr class="odd">
<td><strong>One Africa (16%)</strong></td>
<td>SA private 1.3x market (6.2% vs. 4.7%); #2 Rx rank; tender/new launches.</td>
<td>Margin expansion H2 FY26; sustained 5-10% USD growth.</td>
</tr>
<tr class="even">
<td><strong>EMEU (13%)</strong></td>
<td>Deep penetration (DTM/B2B); highest-ever $110 Mn Q.</td>
<td>15%+ USD YoY trajectory.</td>
</tr>
<tr class="odd">
<td><strong>Overall</strong></td>
<td>GLP-1 obesity wave; biosimilars/GLP-1 supply (CMO capacity secured); R&amp;D acceleration (complex generics, peptides, oligo). FY26 rev growth ~8-10% implied.</td>
<td>10-15% CAGR medium-term; $1B+ US, India obesity double-digit upside.</td>
</tr>
</tbody>
</table>
</div>
<div id="key-risks" class="section level6">
<h6>Key Risks</h6>
<ol style="list-style-type: decimal">
<li><strong>US Pipeline Delays/Revlimid Cliff</strong>: Launches FDA-dependent; Revlimid FY26 &lt;50% FY25 (Q3 nil-like). Abraxane/Nanopaclitaxel behind targets initially.</li>
<li><strong>Competition</strong>: GLP-1 (semaglutide multi-player vs. tirzepatide differentiation); US generics (lanreotide filings); India respiratory seasonality.</li>
<li><strong>Regulatory</strong>: USFDA reinspection (Indore); ongoing litigation (e.g., QVAR).</li>
<li><strong>Margin Erosion</strong>: R&amp;D ramp (new programs); marketing spend up 11% YoY; forex/pricing pressures.</li>
<li><strong>Execution/Transition</strong>: Leadership change; India growth regain; sales force for GLP-1 (dedicated but scaling needed).</li>
<li><strong>Macro</strong>: Tender volatility (Africa); GST/inflation in India; global supply chain (GLP-1 CMO reliance).</li>
</ol>
</div>
<div id="summary" class="section level6">
<h6>Summary</h6>
<p><strong>Bull Case</strong>: Cipla’s diversified model shines with record revenue/margins, cash-rich balance sheet, and GLP-1 entry (Yurpeak) unlocking India obesity (~INR 10,000 Cr+ TAM). US pipeline + biosimilars position for $1B+ run-rate; chronic/consumer tailwinds support 10-15% growth. Leadership transition smooth.</p>
<p><strong>Bear Case</strong>: Revlimid drop + higher R&amp;D pressures FY26 margins (22.75-24%); India Rx lag; regulatory hurdles could cap upside.</p>
<p><strong>Valuation Context</strong>: Trading at ~35-40x FY26 EPS (pre-results est.); focus on FY27 recovery (post-launches). <strong>Rating: Accumulate</strong> – Strong fundamentals offset near-term US headwinds; monitor Q3 Revlimid actuals and US approvals. Target upside 15-20% in 12M on pipeline execution.</p>
<p><em>(Analysis purely from provided docs; no external data/models used.)</em></p>
</div>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
